Ellen T. Matloff on Genetic Recommendations for BRCA1/2 Carriers
Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses options for BRCA1/2 carriers who are looking to reduce their risk of ovarian cancer.
Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses options for BRCA1/2 carriers who are looking to reduce their risk of ovarian cancer.
Matloff recommends that all BRCA1/2 carriers should seek the advice of a certified genetic counselor. The counselor will sit down with the carrier and go over all of their mutations before conducting a four-generation, personal and family history assessment and going over all of their options.
If the patient has had 20 years of birth control pill use, for example, she’s already greatly reduced her risk of ovarian cancer, Matloff explains. A more personalized approached needs to be taken when discussing risk-reducing options, Matloff says.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
